Search This Blog

Thursday, September 14, 2023

A New Way To Think About Equity Volatility

 By Russell Clark, author of the Capital Flows and Asset Markets substack

I have been fascinated by “volatility” markets for years.

Products that sell volatility to generate yield (or converting the premium you receive from selling volatility into a form of fixed income) - autocallables - have been an interest for me for years. Over the years we have seen various blow-ups in the volatlity markets - HSCEI in 2015/6, KOSPI in 2019. Back in GFC, Japanese autocallable products, particularly in currency markets proved to be totally disastrous. Most investors should remember the overnight implosion of XIV, a short VIX ETF, in 2018.

One of the things that I started to look at was trying to work out when volatility is “mispriced”.

That is when in my view that volatility selling products had pushed volatility to unsustainable low levels. One of my favorite examples of this was Korea, which in recent years has become the single biggest market for equity autocallable products. From 2003 to 2012, VKOPSI (VIX for KOSPI 200) rarely traded below 20. From 2012 onwards it rarely traded above 20, until we hit Covid and 2022 tech sell off - but here today we are trading back at close to record lows.

I noted that the collapse in Kospi volatility coincided with the sharp increase in Korean issuance of autocallables.

I started to think that the tail was wagging the dog. Looking at the way clearinghouses prices risk, I could see a world where momentum strategies would drive volatility lower and markets higher, and then cause a massive unwind. In many ways, what we saw in the GFC. The problem with the view was that governments now take a very dim view of financial instability. When I look at VIX, and compare it to high yield spreads, another measure of financial risk, the correlation is very high, and with no real change in the relationship since 1995, despite the rise of volatility selling.

The big difference to the 1990s, or even the 2000s, is that governments are extremely pro-active in stabilising markets. The Federal Reserve guaranteed high yield bonds during Covid, and governments have a “spend what it takes” attitude to economic growth. US and China are taking divergent view on markets. The US seems more comfortable with doing whatever it takes to keep markets growing, while China wants lower property prices, and is happy to see property developers go bankrupt to achieve that end. Due to this political divergence, see that the correlations between VHSCEI (China) and VIX (US) is weakening. In 2015, the move higher in VHSCEI was driven my currency devaluation fears, but the recent move higher is more politically driven in my view.

So post GFC, volatility markets, as they are tied to credit markets which represent the willingness of governments to backstop those markets. From that perspective, Europe has much more closely followed the US.

The relative volatility of EuroStoxx 50 also matches up with the political changes in Europe. From 2011 onwards, there was more political risk in European markets than in the US. Even though the ECB acted to stabilise markets, there was no political agreement. With Covid, and more united approach to Europe by European governments has appeared, the premium of European vol to US vol has collapsed. From an economic point of view, the war in Ukraine should lead to Eurostoxx Vol trading at a premium, but politically, the collapsing vol premium makes sense.

So for volatility traders, what does this analysis mean? Well the low levels in the US, Korea and Europe accurately reflect government attitudes towards markets. While Biden talks up taking on big corporates, with an election year coming up, strong stock markets are probably better for him. One market where problems of income inequality and over powerful corporates is not an issue is Japan. Here both government and central bank policy is still pro-capital. From this perspective, I could almost argue that VNKY should trade inside VIX, which in recent years it has started to do, this in sharp contrast to the trend from 2003 to 2019.

Recently VNKY has spiked over VIX, so for volatility traders, a short VNKY perhaps hedged with a long VIX looks interesting.

Politics trumps economics is the lesson I have learnt the hard way. Politically it feels there is less political risk in Japan, so this premium in VNKY look like an opportunity. However, this view is based on a political judgement, which means it could change quickly if politics changes.


Abcam founder Jonathan Milner opposes Danaher deal

 Jonathan Milner, the founder and one of the largest investors in Abcam Plc, on Thursday announced his decision to vote against Danaher's proposed acquisition of the protein consumables manufacturer.

Milner, who owns 6.14% of Abcam, said he will formally request the board for a general meeting to replace the board including the chief executive, chief financial officer and chairman.

https://finance.yahoo.com/news/abcam-founder-jonathan-milner-opposes-122851506.html

HealthStream Announces Share Repurchase Program

 HealthStream (Nasdaq: HSTM), a leading healthcare technology platform for workforce solutions, today announced that its Board of Directors has approved a new share repurchase program for the Company’s common stock, under which the Company may repurchase up to $10 million of outstanding shares of common stock.

Pursuant to the authorization, repurchases may be made from time to time in the open market, including under a Rule 10b5-1 plan, through privately negotiated transactions, or otherwise. In addition, any repurchases under the authorization will be subject to prevailing market conditions, liquidity and cash flow considerations, applicable securities laws requirements (including under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as applicable), and other factors. The share repurchase program will terminate on the earlier of March 31, 2024 or when the maximum dollar amount has been expended. The share repurchase program does not require the Company to acquire any amount of shares and may be suspended or discontinued at any time.

https://finance.yahoo.com/news/healthstream-announces-share-repurchase-program-203000848.html

Bristol Myers plans to double experimental treatments to expand research pipeline

 Bristol Myers Squibb said on Thursday it plans to double the number of treatments it is testing in clinical trials, with a focus on cell therapies, over the next 18 months, as it contends with increasing generic competition for two of its top-selling drugs.

The drugmaker, which currently has six candidates in trials, will advance six more in its research pipeline - including three cell therapies that target immune system disorders and different types of cancer.

The New York-based company has been pressured by declining demand for two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, which face generic competition.

Bristol and partner Pfizer's blood thinner Eliquis was also on the list of 10 drugs that will be subject to the first-ever price negotiations by the U.S. Medicare health program.

The company recently received regulatory approval for a new cell therapy manufacturing facility in Devens, Massachusetts and Bristol said it will continue expanding its manufacturing capacity.

Bristol, which already has two approved cell therapies in the U.S., Breyanzi and Abecma, targeting different blood cancer indications, said it plans to continue development for treatment of other diseases such as lupus erythematosus and multiple sclerosis.

The drugmaker is hosting an R&D day on Thursday, where executives are expected to provide details of the company's research strategy.

https://finance.yahoo.com/news/bristol-myers-plans-double-experimental-124829672.html

U.S. Bank Initiative to Serve Small-to-Midsize Healthcare Practices

 U.S. Bank today announced a new cross-business initiative to serve healthcare practices with up to $25 million in annual revenue. Newly appointed Head of Healthcare Business Banking Joe Persichetti will lead this effort, working with teams across banking, payments, and wealth management to deliver a comprehensive suite of solutions for healthcare clients.

U.S. Bank is adding more than 50 new positions across the country to power the initiative, combining high-touch service with healthcare expertise and tailored solutions. Each client will be served by a specialized team led by a healthcare banker who can bring them solutions and advice designed to strengthen their practice, improve their patient payment experience, and help them achieve their personal financial goals.

Clients will include medical, dental, and veterinary practices and practice owners, as well as physician-owned medical and diagnostic laboratories and outpatient care centers. U.S. Bank will have healthcare business banking relationship managers located in strategic markets across its footprint.

While banks have traditionally focused their healthcare services on hospitals and large medical systems, more than 50% of practitioners are in small to mid-size practices. These practices need services that will simplify their finances and operations, so their practitioners can spend more time on patients and less time on administrative tasks.

https://finance.yahoo.com/news/u-bank-launches-initiative-serve-130000370.html

Edgewise Starts Phase 1 for for Hypertrophic Cardiomyopathy Candidate

 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500. EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. The Phase 1 trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of EDG-7500 in healthy adults. The Company is also planning to begin a Phase 1b study of EDG-7500 in individuals with obstructive HCM in the first half of 2024.

https://finance.yahoo.com/news/edgewise-therapeutics-begins-dosing-first-120000202.html

Moderna Axes Four Clinical Development Programs, Two AstraZeneca Had Dropped

 Moderna on Wednesday announced it was dropping four clinical development programs from its roster, including two molecules that had also been previously culled by AstraZeneca.

The decision to discontinue the four clinical programs was part of Moderna’s routine review of its pipeline, in which it evaluates whether there are better opportunities and areas of focus for its mRNA-based drug discovery, design and development platform, President Stephen Hoge said during the company’s annual R&D Day.

“We have a blessing and a curse in terms of how productive this platform is, and anytime we see an opportunity to focus our energy on programs that we think are the most important to move forward, we’ll do so,” Hoge said.

Moderna’s pipeline cull will affect two formerly AstraZeneca-partnered molecules: the VEGF-A program AZD8601 and the IL-12 program MEDI1191.

AZD8601 is an mRNA therapeutic encoding for VEGF-A. In November 2021, Moderna posted data from the AstraZeneca-led Phase II EPICCURE study, which found that injecting the candidate into heart tissue was safe and tolerable, while eliciting signals of efficacy such as improved left ventricular ejection fraction and patient-reported outcomes.

AstraZeneca announced it was dropping AZD8601 from its roster in August 2022.

A few months later, in November 2022, AstraZeneca also pulled its support from the IL-12 program MEDI1191, which it was studying as part of a combination regimen with the PD-L1 inhibitor durvalumab for the treatment of advanced solid tumors. MEDI1191 is a lipid nanoparticle-formulated candidate that induces the production of IL-12 and promotes anti-tumor activity.

In addition to these two candidates, Moderna announced during Wednesday’s R&D Day that it was likewise dropping mRNA-1653, the company’s vaccine candidate for pediatric human metapneumovirus and parainfluenza type 3 virus. The investigational shot was being assessed in a Phase Ib study.

Moderna is also abandoning its first-generation COVID-19 and flu combination vaccine mRNA-1073. During its 2022 R&D Day, the company announced that it was assessing the candidate in a Phase I/II trial. Moderna is also advancing a triple-target vaccine, mRNA-1230, which is likewise in a Phase I/II study for COVID-19, flu and respiratory syncytial virus.

The news about culling four programs from its pipeline came the same day as the Massachusetts-based biopharma celebrated a Phase III victory for its mRNA-based flu vaccine candidate. Also revealed during Wednesday’s R&D Day, the investigational shot—dubbed mRNA-1010—met all its co-primary endpoints across all four influenza A and B strains, according to an interim analysis of the late-stage study.

https://www.biospace.com/article/moderna-axes-four-clinical-development-programs-two-astrazeneca-previously-dropped-/